aaATIIIAlternative Names: Antithrombin III - modified
Latest Information Update: 12 Mar 2001
At a glance
- Originator Childrens Hospital Boston
- Class Antineoplastics; Antithrombins; Biological proteins
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer